Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

Conditions

• Breast Cancer - Infiltrating Ductal Carcinoma
• HER-2 Positive Breast Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy — DRUG
  Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

Study Details

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

Key Dates

Start date

Apr 27, 2026

Status verified

Apr 2026

Primary completion

Dec 31, 2027

Completion

Dec 31, 2027

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

Primary Outcome Measure

pCR Rates [ Time Frame: 21 months ]

Locations (4)

Find similar trials in Gresham, OR

Related Studies

• Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
  Recruiting · Innoblative Designs, Inc. · Galveston, Texas
• Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer
  Not Yet Recruiting · University of Vermont Medical Center · Burlington, Vermont